1,488 results match your criteria: "Institute for Research on Alzheimer's Disease and the Aging Brain[Affiliation]"

Estimating dementia prevalence using remote diagnoses and algorithmic modelling: a population-based study of a rural region in South Africa.

Lancet Glob Health

December 2024

Harvard Center for Population and Development Studies, Harvard University, Cambridge, MA, USA; Department of Social and Behavioral Sciences, Harvard T H Chan School of Public Health, Harvard University, Cambridge, MA, USA; MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Background: Dementia is a leading cause of global death and disability. High-quality data describing dementia prevalence and burden remain scarce in sub-Saharan Africa. Health and Aging in Africa: A Longitudinal Study in South Africa (HAALSI) fills evidence gaps with longitudinal data on cognition, biomarkers, and everyday function in a population-based cohort of Black South Africans, aged 40 years and older, in a rural subdistrict.

View Article and Find Full Text PDF

APOE ε4-associated heterogeneity of neuroimaging biomarkers across the Alzheimer's disease continuum.

Alzheimers Dement

January 2025

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.

Introduction: While the role of apolipoprotein E (APOE) ε4 in Alzheimer's disease (AD) susceptibility has been studied extensively, much less is known about the differences in disease presentation in APOE ε4 carriers versus non-carriers.

Methods: To help elucidate these differences, we performed a broad analysis comparing the regional levels of six different neuroimaging biomarkers in the brains of APOE ε4 carriers versus non-carriers who participated in the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Results: We observed significant APOE ε4-associated heterogeneity in regional amyloid beta deposition, tau accumulation, glucose uptake, brain volume, cerebral blood flow, and white matter hyperintensities within each AD diagnostic group.

View Article and Find Full Text PDF

Astrocytes are key regulators of central nervous system (CNS) homeostasis, and their dysfunction is implicated in neurological and neurodegenerative disorders. Here, we describe a two-step protocol to generate astrocytes from human induced pluripotent stem cells (hiPSCs) using a bankable neural progenitor cell (NPC) intermediate, followed by low-density passaging and overexpression of the gliogenic transcription factor NFIA. A bankable NPC intermediate allows for facile differentiation into both purified neuronal and astrocyte cell types in parallel from the same genetic background, depending on the experimental needs.

View Article and Find Full Text PDF

A microglia-containing cerebral organoid model to study early life immune challenges.

Brain Behav Immun

January 2025

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Human Genetics, Radboud UMC, Nijmegen, Netherlands (the); Donders Institute for Brain, Cognition and Behaviour, 6500 HB, Nijmegen, Netherlands (the); Department of Psychiatry, Radboud UMC, Nijmegen, Netherlands (the).

Prenatal infections and activation of the maternal immune system have been proposed to contribute to causing neurodevelopmental disorders (NDDs), chronic conditions often linked to brain abnormalities. Microglia are the resident immune cells of the brain and play a key role in neurodevelopment. Disruption of microglial functions can lead to brain abnormalities and increase the risk of developing NDDs.

View Article and Find Full Text PDF

In recent years, multiple groups have shown that what is currently thought of as "Alzheimer's Disease" (AD) may be usefully viewed as several related disease subtypes. As these efforts have continued, a related issue is how common co-pathologies and ethnicity intersect with AD subtypes. The goal of this study was to use a dataset constituting 153 pathologic variables recorded on 666 AD brain autopsies to better define how co-pathologies and ethnicity relate to established AD subtypes.

View Article and Find Full Text PDF

Objective: To examine the impact of 40Hz gamma stimulation on the preservation of the corpus callosum, a critical structure for interhemispheric connectivity, in people with mild cognitive impairment or Alzheimer's disease.

Methods: OVERTURE (NCT03556280) participants were randomized 2:1 (Active:Sham) to receive daily, 1-h, 40Hz gamma sensory stimulation or sham treatment for 6 months. Structural magnetic resonance imaging data were analyzed to assess changes in corpus callosum area ( = 50; 33 for active, 17 for sham).

View Article and Find Full Text PDF
Article Synopsis
  • Neurodegenerative tauopathies are linked to unique tau fibril structures, which correlate with specific disease characteristics.
  • Essential tremor (ET) can involve tau accumulation and cognitive issues, leading researchers to use tau biosensor assays to analyze brain samples from ET patients.
  • The study found that tau properties in some ET patients closely match those seen in Alzheimer's disease and related tauopathies, suggesting potential for better diagnosis and understanding of ET-related tau pathology.
View Article and Find Full Text PDF

Human brain tissue studies have historically used a range of metrics to assess RNA quality. However, few large-scale cross-comparisons of pre-sequencing quality metrics with RNA-seq quality have been published. Here, we analyze how well metrics gathered before RNA sequencing (post-mortem interval (PMI) and RNA integrity number RIN) relate to analyses of RNA quality after sequencing (Percent of counts in Top Ten genes (PTT), 5' bias, and 3' bias) as well as with individual gene counts across the transcriptome.

View Article and Find Full Text PDF
Article Synopsis
  • Genetic research on Alzheimer's disease (AD) has largely concentrated on amyloid-β (Aβ), while this study focuses on understanding the genetic basis of tau pathology to uncover new pathways related to AD.
  • A genome-wide association study (GWAS) was conducted using data from the A4 and ADNI studies to analyze genetic variants linked to tau pathology, finding two significant loci and pinpointing certain genes associated with tau deposition.
  • Mendelian randomization analyses suggest that the LRRFIP1 protein may have a causal relationship with tau pathology, while the polygenic risk scores showed strong associations with amyloid pathology but not with tau pathology.
View Article and Find Full Text PDF

HDAC Inhibitors recapitulate Human Disease-Associated Microglia Signatures .

bioRxiv

October 2024

Center for Translational & Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center.

Disease-associated microglia (DAM), initially described in mouse models of neurodegenerative diseases, have been classified into two related states; starting from a TREM2-independent DAM1 state to a TREM2 dependent state termed DAM2, with each state being characterized by the expression of specific marker genes. Recently, single-cell (sc)RNA-Seq studies have reported the existence of DAMs in humans; however, whether DAMs play beneficial or detrimental roles in the context of neurodegeneration is still under debate. Here, we present a pharmacological approach to mimic human DAM by exposing different human microglia models to selected histone deacetylase (HDAC) inhibitors.

View Article and Find Full Text PDF

Human microglia play a pivotal role in neurological diseases, but we still have an incomplete understanding of microglial heterogeneity, which limits the development of targeted therapies directly modulating their state or function. Here, we use single-cell RNA sequencing to profile 215,680 live human microglia from 74 donors across diverse neurological diseases and CNS regions. We observe a central divide between oxidative and heterocyclic metabolism and identify microglial subsets associated with antigen presentation, motility and proliferation.

View Article and Find Full Text PDF
Article Synopsis
  • By age 40, over 90% of adults with Down syndrome develop Alzheimer’s disease, with many progressing to dementia, despite having few typical vascular risk factors.
  • This study analyzed how small vessel cerebrovascular disease impacts Alzheimer's disease progression and neurodegeneration in adults with Down syndrome, using MRI and plasma biomarker data from 185 participants.
  • Results indicated a complex relationship where white matter hyperintensity (WMH) levels influenced phosphorylated tau, linked by glial fibrillary acidic protein, suggesting that cerebrovascular health affects Alzheimer’s pathology in this population.
View Article and Find Full Text PDF

A platform to map the mind-mitochondria connection and the hallmarks of psychobiology: the MiSBIE study.

Trends Endocrinol Metab

October 2024

Division of Behavioral Medicine, Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; H. Houston Merritt Center for Neuromuscular and Mitochondrial Disorders, Columbia Translational Neuroscience Initiative, Department of Neurology, Columbia University Medical Center, New York, NY, USA; Robert N. Butler Columbia Aging Center, Columbia University Mailman School of Public Health, New York, NY, USA; New York State Psychiatric Institute, New York, NY, USA. Electronic address:

Article Synopsis
  • Health is influenced by mitochondrial energy transformation, which plays a crucial role in regulating various body systems that relate to resilience and disease risk throughout life.
  • The MiSBIE study aims to explore how mitochondria affect interconnected systems like neuroendocrine, immune, and cognitive functions, focusing on individuals with mitochondrial diseases.
  • This research seeks to enhance understanding of mitochondrial diseases, develop new health biomarkers, and better integrate knowledge of the connections between energy processes and overall health.
View Article and Find Full Text PDF
Article Synopsis
  • - The text indicates a correction made to an article, identified by its DOI: 10.3389/fnagi.2024.1419253.
  • - The correction likely addresses issues such as errors in data, methodology, interpretation, or citations presented in the original article.
  • - This update is important for maintaining the accuracy and reliability of the research published in the journal.
View Article and Find Full Text PDF

Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome.

EBioMedicine

October 2024

Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain. Electronic address:

Article Synopsis
  • Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) are genetic forms of Alzheimer's that help researchers explore biomarker changes and disease progression in Alzheimer's overall.
  • The study highlights that biomarkers in genetic cases have unique characteristics and a predictable onset, making their context of use different from sporadic Alzheimer's cases.
  • Understanding these distinctions is crucial for research and clinical practices, ultimately leading to more personalized treatment strategies for individuals affected by genetically determined Alzheimer's.
View Article and Find Full Text PDF

Individuals at clinical high-risk (CHR) of developing psychosis, as well as patients with recent psychosis onset (RO), experience significant negative symptoms that detrimentally impact daily-life functioning and are associated with poor outcomes, even in those who do not convert to psychosis. Targeting negative symptoms may thus hold promise for the treatment of CHR and RO patients. Building from previous findings we examined whether the catechol-O-methyltransferase (COMT) ValMet functional polymorphism and fasting peripheral proline concentration predicts the severity of negative symptoms experienced by adolescents and young adults at CHR or those with RO.

View Article and Find Full Text PDF

Introduction: It is important to understand the socioeconomic and medical determinants of subjective cognitive decline (SCD) at a population level in the United States.

Methods: The primary outcomes are state-level rates of SCD and SCD-related functional impairment in adults aged ≥ 45, both measured in the Behavioral Risk Factor Surveillance System from 2016 to 2022. The exposures are state-level rates of poverty, unemployment, homelessness, college education, racial and ethnic minorities, uninsurance, smoking, hypertension, diabetes, and obesity as well as household income and physician density.

View Article and Find Full Text PDF

Large-scale genetic studies have identified numerous genetic risk factors that suggest a central role for innate immune cells in susceptibility to Alzheimer's disease (AD). CD33, an immunomodulatory transmembrane sialic acid binding protein expressed on myeloid cells, was identified as one such genetic risk factor associated with Alzheimer's disease. Several studies explored the molecular outcomes of genetic variation at the locus.

View Article and Find Full Text PDF

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.

eNeuro

September 2024

Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the GH Sergievsky Center, Columbia University Irving Medical Center, New York, New York 10032

Article Synopsis
  • The FDA approved aducanumab in 2021, marking a significant breakthrough in Alzheimer's disease treatment, with two more drugs, lecanemab and donanemab, receiving similar approvals in early 2023 and mid-2024.
  • These therapies, which target β-amyloid aggregates, have shown promising results in slowing cognitive decline in clinical trials.
  • Ongoing discussions focus on the application of trial results to real-world scenarios and the overall long-term benefits of these treatments, along with the implications of FDA approval conditions on their usage in clinical practice.
View Article and Find Full Text PDF

Background: Education is strongly associated with cognitive outcomes at older ages, yet the extent to which these associations reflect causal effects remains uncertain due to potential confounding.

Methods: Leveraging changes in historical measures of state-level education policies as natural experiments, we estimated the effects of educational attainment on cognitive performance over 10 years in 20,248 non-Hispanic Black and non-Hispanic White participants, aged 45+ in the Reasons for Geographic and Racial Disparities in Stroke cohort (2003-2020) by (1) using state- and year-specific compulsory schooling laws, school-term length, attendance rate, and student-teacher ratio policies to predict educational attainment for US Census microsample data from 1980 and 1990, and (2) applying policy-predicted years of education (PPYEd) to predict memory, verbal fluency, and a cognitive composite. We estimated overall and race- and sex-specific effects of PPYEd on level and change in each cognitive outcome using random intercept and slope models, adjusting for age, year of first cognitive assessment, and indicators for state of residence at age 6.

View Article and Find Full Text PDF

Gene-Specific Effects on Brain Volume and Cognition of in Frontotemporal Lobar Degeneration.

Neurology

October 2024

From the VIB Center for Molecular Neurology (M.V., R.R., V.B., S.W.); Department of Biomedical Sciences (M.V., M.V.B., S.W., R.R.), University of Antwerp, Belgium; Department of Neurology (E.M.R., M.F.M.), David Geffen School of Medicine, University of California, Los Angeles; Department of Neurology (N.C.-L., V.K.R., T.K., K.K., B.F.B.); Department of Psychiatry and Psychology (N.C.-L., J.A.F., D.S.K., L.K.F.), Mayo Clinic, Rochester, MN; Department of Epidemiology and Biostatistics (J.K.), University of California, San Francisco; Department of Quantitative Health Sciences (C.M., D.E.B.), Mayo Clinic, Rochester, MN; Department of Neurology (A.M.S., A.A.W.), Memory and Aging Center, University of California, San Francisco; Weill Institute for Neurosciences, San Francisco, California; Institute for Precision Health (D.H.G.), Departments of Neurology, Psychiatry and Human Genetics at David Geffen School of Medicine, UCLA; Department of Neuroscience (T.G., L.P., M.B., N.R.G.-R.), Mayo Clinic, Jacksonville, FL; Alzheimer's Disease and Other Cognitive Disorders Unit (S.B.-É.), Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Fundació Clínic per a la Recerca Biomèdica, Uni; Department of Neurology (B.A., B.C.D.), Case Western Reserve University, Cleveland, OH; Department of Neurology (S.B.), University of Michigan, Ann Arbor; Department of Neurology (A.C.B.), University of North Carolina, Chapel Hill; Department of Neurology (D.C.), Indiana University, Indianapolis; Department of Neurology (R.R.D.), Vanderbilt University, Nashville, TN; Department of Neurology (K.D.-R.), University of Washington, Seattle, WA; Department of Neurosciences (D.G., G.C.L., I.L.), University of California, San Diego, La Jolla; Departments of Neurology and Psychiatry (N.G.), Washington University School of Medicine, Washington University, St. Louis, MO; Department of Psychiatry and Behavioral Sciences (I.M.G.), Northwestern Feinberg School of Medicine, Chicago, IL; Taub Institute for Research on Alzheimer's Disease and the Aging Brain (L.S.H.), College of Physicians and Surgeons; Department of Neurology (L.S.H.), Columbia University, New York; Division of Neurology (G.-Y.R.H.), University of British Columbia, Vancouver, Canada; Department of Psychiatry and Human Behavior (E.D.H.), Alpert Medical School of Brown University, Providence, RI; Department of Neurology and Penn Frontotemporal Degeneration Center (D.J.I.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; National Institute of Neurological Disorders and Stroke (J.Y.K., A.S.), National Institutes of Health, Bethesda, MD; Department of Neurology (J.C.M., B.P.), Houston Methodist, TX; Department of Psychiatry and Behavioral Sciences (C.U.O.), Johns Hopkins University, Baltimore, MD; Department of Neurology (P.S.P.), University of Colorado, Aurora; Cleveland Clinic Lou Ruvo Center for Brain Health (A.R., D.W.), Las Vegas, NV; Department of Neurology (E.D.R.), University of Alabama at Birmingham; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases (A.C.S.), UT Health San Antonio; Tanz Centre for Research in Neurodegenerative Diseases (M.C.T.), Division of Neurology, University of Toronto, Ontario, Canada; Department of Neurology (H.W.H., A.L.B., H.J.R.), Memory and Aging Center, University of California, San Francisco; Weill Institute for Neurosciences, San Francisco, CA; and Department of Neuroscience (R.R.), Mayo Clinic, Jacksonville, FL.

Article Synopsis
  • The study investigates the role of the genetic variant rs1990622 as a potential modifier of disease risk in frontotemporal lobar degeneration (FTLD), particularly among those with pathogenic variants.
  • Researchers enrolled participants from the ALLFTD study, analyzing the impact of rs1990622 on gray matter volume and cognitive function across various genetic groups related to FTD.
  • Results indicate that carriers of the minor allele of rs1990622 show increased gray matter volume and better cognitive performance, especially in the thalamus and among presymptomatic individuals.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the genetic factors contributing to Alzheimer's disease by analyzing tau deposition through a genome-wide association study involving 3,046 participants.
  • It identifies the CYP1B1-RMDN2 locus as significantly linked to tau levels, with the variant rs2113389 explaining 4.3% of tau variation, while also correlating with cognitive decline.
  • Findings suggest a connection between CYP1B1 expression and tau deposition, offering potential new avenues for Alzheimer's treatment and understanding its genetic basis.
View Article and Find Full Text PDF

Regulation of synapse density by Pumilio RNA-binding proteins.

Cell Rep

October 2024

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. Electronic address:

The formation, stabilization, and elimination of synapses are tightly regulated during neural development and into adulthood. Pumilio RNA-binding proteins regulate the translation and localization of many synaptic mRNAs and are developmentally downregulated in the brain. We found that simultaneous downregulation of Pumilio 1 and 2 increases both excitatory and inhibitory synapse density in primary hippocampal neurons and promotes synapse maturation.

View Article and Find Full Text PDF

Association of Adherence to a MIND-Style Diet With the Risk of Cognitive Impairment and Decline in the REGARDS Cohort.

Neurology

October 2024

From the Department of Neurology and Rehabilitation Medicine (R.P.S., R.S.), University of Cincinnati College of Medicine, OH; Biostatistics Department (J.B., S.E.J.), School of Public Health, University of Alabama at Birmingham; Taub Institute for Research on Alzheimer's Disease and the Aging Brain (J.J.M.), G.H. Sergievsky Center (J.J.M.), and Department of Neurology (J.J.M.), Vagelos College of Physicians and Surgeons, Columbia University, New York Presbyterian Hospital, New York.

Background And Objectives: Diet may influence the development of cognitive impairment and affect cognitive decline, but whether this relationship varies between Black American and White American people is unclear. This study examined the association of Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) and incident cognitive impairment and cognitive trajectories in a biracial prospective cohort study.

Methods: Using data derived from the Food Frequency Questionnaire in the REasons for Geographic and Racial Differences in Stroke study, we compared MIND diet adherence with incident cognitive impairment and cognitive trajectory in Black participants and White participants.

View Article and Find Full Text PDF

Missense and loss-of-function variants at GWAS loci in familial Alzheimer's disease.

Alzheimers Dement

November 2024

Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA.

Background: Few rare variants have been identified in genetic loci from genome-wide association studies (GWAS) of Alzheimer's disease (AD), limiting understanding of mechanisms, risk assessment, and genetic counseling.

Methods: Using genome sequencing data from 197 families in the National Institute on Aging Alzheimer's Disease Family Based Study and 214 Caribbean Hispanic families, we searched for rare coding variants within known GWAS loci from the largest published study.

Results: Eighty-six rare missense or loss-of-function (LoF) variants completely segregated in 17.

View Article and Find Full Text PDF